Rafarma Pharmaceuticals, Inc. (RAFA) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Rafarma Pharmaceuticals, Inc. (RAFA) opera en el sector Healthcare, cotizado por última vez a $ con una capitalización de mercado de 0. Calificado con 44/100 (cauteloso) en potencial de crecimiento, salud financiera e impulso.
Ultimo analisis: 17 mar 2026Rafarma Pharmaceuticals, Inc. (RAFA) Resumen de Asistencia Médica y Tuberías
Rafarma Pharmaceuticals, Inc. produces and distributes generic antibiotics and specialty pharmaceuticals in Russia, including cephalosporin-based and anti-cancer drugs. Operating as a subsidiary of R. & D. Biocogency Laboratories Inc. Ltd., it navigates the competitive landscape of the Russian pharmaceutical market with a focus on various drug formulations.
Tesis de Inversión
Rafarma Pharmaceuticals, Inc. presents a focused investment opportunity within the Russian pharmaceutical market, specializing in generic antibiotics and specialty drugs. With a market capitalization of $0.01 billion and a P/E ratio of 19.50, the company demonstrates potential for growth, supported by a gross margin of 7.3% and a profit margin of 3.2%. Key growth catalysts include the collaboration with PlantEXT Ltd. to develop medical cannabis suppositories and the expansion of its product offerings in the Russian market. However, investors may want to evaluate the risks associated with operating in the OTC market and the competitive pressures within the pharmaceutical industry. The company's beta of 0.54 suggests lower volatility compared to the market.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Market capitalization of $0.01 billion indicates a micro-cap company with potential for high growth but also higher risk.
- P/E ratio of 19.50 suggests the company is trading at a moderate valuation compared to its earnings.
- Gross margin of 7.3% reflects the company's profitability after accounting for the cost of goods sold.
- Profit margin of 3.2% indicates the percentage of revenue that turns into profit after all expenses, including taxes, are paid.
- Beta of 0.54 suggests the stock is less volatile than the overall market.
Competidores y Pares
Fortalezas
- Established manufacturing facility in Russia.
- Focus on generic antibiotics and specialty pharmaceuticals.
- Collaboration with PlantEXT Ltd. for innovative products.
- Diverse product portfolio addressing various medical needs.
Debilidades
- Small market capitalization.
- Low gross and profit margins.
- Reliance on the Russian market.
- OTC market listing.
Catalizadores
- Ongoing: Expansion of product portfolio with new generic drugs and specialty pharmaceuticals.
- Ongoing: Collaboration with PlantEXT Ltd. to develop and commercialize medical cannabis suppositories.
- Ongoing: Geographic expansion within Russia to reach a wider customer base.
- Upcoming: Potential strategic acquisitions and partnerships to expand market presence (Timeline: 2027).
- Upcoming: Exploration of export opportunities to diversify revenue streams (Timeline: 2027-2028).
Riesgos
- Ongoing: Intense competition from domestic and international pharmaceutical companies.
- Potential: Regulatory changes in the Russian pharmaceutical market affecting pricing and market access.
- Potential: Economic instability in Russia impacting demand for pharmaceutical products.
- Potential: Fluctuations in currency exchange rates affecting profitability.
- Ongoing: Risks associated with operating on the OTC Other tier, including limited liquidity and transparency.
Oportunidades de crecimiento
- Expansion of Product Portfolio: Rafarma can expand its product portfolio by introducing new generic drugs and specialty pharmaceuticals to address unmet medical needs in the Russian market. This includes investing in research and development to create innovative formulations and dosages. The market for generic drugs is expected to grow as patents for branded drugs expire, providing a significant opportunity for Rafarma to increase its revenue and market share. Timeline: Ongoing.
- Collaboration with PlantEXT Ltd.: The collaboration with PlantEXT Ltd. to research and manufacture medical cannabis suppositories for patients suffering from inflammatory bowel disease presents a unique growth opportunity. The market for medical cannabis is expanding globally, and Rafarma can leverage this partnership to enter a new and potentially lucrative market segment. Successful development and commercialization of these suppositories could significantly boost the company's revenue and brand recognition. Timeline: Ongoing.
- Geographic Expansion within Russia: Rafarma can expand its geographic reach within Russia by establishing new distribution channels and partnerships with local pharmacies and healthcare providers. This will allow the company to reach a wider customer base and increase its sales volume. The Russian pharmaceutical market is vast and diverse, with significant regional variations in demand and healthcare infrastructure. Timeline: Ongoing.
- Strategic Acquisitions and Partnerships: Rafarma can pursue strategic acquisitions and partnerships with other pharmaceutical companies to expand its product portfolio, access new technologies, and enter new markets. This includes acquiring companies with complementary product lines or technologies, as well as forming partnerships with research institutions and universities to develop new drugs and therapies. Timeline: Ongoing.
- Focus on Export Markets: Rafarma can explore opportunities to export its products to other countries in the region, particularly those with similar healthcare needs and regulatory environments. This will allow the company to diversify its revenue streams and reduce its reliance on the Russian market. The export market for generic drugs is growing rapidly, driven by increasing demand for affordable healthcare solutions in developing countries. Timeline: 2027-2028.
Oportunidades
- Expansion of product portfolio with new generic drugs.
- Geographic expansion within Russia.
- Strategic acquisitions and partnerships.
- Growth in the medical cannabis market.
Amenazas
- Intense competition from domestic and international players.
- Regulatory changes in the Russian pharmaceutical market.
- Economic instability in Russia.
- Fluctuations in currency exchange rates.
Ventajas competitivas
- Established manufacturing and distribution facility in Russia.
- Collaboration with PlantEXT Ltd. for medical cannabis suppositories.
- Focus on generic antibiotics and specialty pharmaceuticals.
- Product portfolio addressing various medical needs.
Acerca de RAFA
Rafarma Pharmaceuticals, Inc., originally named Johnston Acquisition Corp. before its renaming in October 2012, is a multi-product pharmaceutical company specializing in the production and sale of drugs, generic antibiotics, and specialty pharmaceuticals within the Russian market. The company's product portfolio includes cephalosporin-based products, antibiotics of non-ß structure, and anti-cancer drugs, available in various forms such as injections, ampulla packaged products, child suspensions, tablets, and capsules. Additionally, Rafarma offers medications for accidental wounds, inflammatory eye diseases, and immunological disorders. Based in Sandy, Utah, Rafarma maintains a manufacturing and distribution facility in Russia, allowing it to serve the local market effectively. A significant collaboration with PlantEXT Ltd. is underway to research and manufacture medical cannabis suppositories targeting patients with inflammatory bowel disease, showcasing the company's innovation efforts. Rafarma Pharmaceuticals, Inc. operates as a subsidiary of R. & D. Biocogency Laboratories Inc. Ltd. since October 19, 2020. The company focuses on providing a range of pharmaceutical products to address various medical needs in the Russian healthcare sector.
Qué hacen
- Produces and sells generic antibiotics in Russia.
- Offers specialty pharmaceuticals for various medical conditions.
- Manufactures cephalosporin-based products.
- Develops anti-cancer drugs in different formulations.
- Provides drugs for accidental wounds and inflammatory eye diseases.
- Researches and manufactures medical cannabis suppositories through a collaboration with PlantEXT Ltd.
Modelo de Negocio
- Develops and manufactures generic and specialty pharmaceutical products.
- Sells products through distribution channels in Russia.
- Generates revenue from the sale of pharmaceutical products.
- Collaborates with other companies for research and development.
Contexto de la Industria
Rafarma Pharmaceuticals, Inc. operates within the Drug Manufacturers - Specialty & Generic industry, which is characterized by intense competition and regulatory scrutiny. The Russian pharmaceutical market, where Rafarma primarily operates, is influenced by government policies, pricing regulations, and local demand for affordable medications. The company's focus on generic antibiotics and specialty drugs positions it to capitalize on the growing demand for cost-effective healthcare solutions. However, it faces competition from both domestic and international players, including BIOE, IGPK, LMLLF, LVVV, and NRPR, requiring continuous innovation and strategic partnerships to maintain market share.
Clientes Clave
- Hospitals and clinics in Russia.
- Pharmacies and drugstores.
- Patients requiring generic antibiotics and specialty pharmaceuticals.
- Healthcare providers prescribing medications.
Finanzas
Gráfico e información
Precio de la acción de Rafarma Pharmaceuticals, Inc. (RAFA): Price data unavailable
Últimas noticias
No hay noticias recientes disponibles para RAFA.
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para RAFA.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para RAFA.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de RAFA en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Liderazgo: Sergey Brusnitsin
CEO
Sergey Brusnitsin serves as the CEO of Rafarma Pharmaceuticals, Inc. While detailed background information is limited, his leadership is crucial for guiding the company's strategic direction and operational execution in the Russian pharmaceutical market. His expertise in pharmaceutical management and market dynamics is essential for navigating the competitive landscape and regulatory environment. Further details on his education and prior experience are not available.
Historial: Specific achievements and milestones under Sergey Brusnitsin's leadership are not detailed in the provided information. However, as CEO, he is responsible for overseeing the company's operations, driving growth, and ensuring the successful development and commercialization of pharmaceutical products. His tenure involves navigating the challenges and opportunities within the Russian healthcare sector.
Información del mercado OTC de RAFA
The OTC Other tier represents the lowest tier of the OTC market, indicating that Rafarma Pharmaceuticals, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and liquidity, and may not be required to provide regular financial disclosures. Investing in companies on the OTC Other tier carries significant risks due to the lack of transparency and regulatory oversight compared to companies listed on major exchanges like NYSE or NASDAQ.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited financial disclosure and transparency.
- Low trading volume and liquidity.
- Potential for price manipulation and fraud.
- Higher risk of delisting or going out of business.
- Lack of regulatory oversight and investor protection.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's legal and regulatory compliance.
- Check for any red flags or warning signs, such as lawsuits or investigations.
- Determine the company's ownership structure and potential conflicts of interest.
- Consult with a financial advisor or legal professional.
- Established manufacturing facility in Russia.
- Focus on generic antibiotics and specialty pharmaceuticals.
- Collaboration with PlantEXT Ltd. for innovative products.
- Company has been in operation since 2012.
- Operates as a subsidiary of R. & D. Biocogency Laboratories Inc. Ltd.
RAFA Preguntas Frecuentes sobre Acciones de Healthcare
¿Cuáles son los factores clave para evaluar RAFA?
Rafarma Pharmaceuticals, Inc. (RAFA) actualmente tiene una puntuación IA de 44/100, indicando puntuación baja. Fortaleza clave: Established manufacturing facility in Russia.. Riesgo principal a monitorear: Ongoing: Intense competition from domestic and international pharmaceutical companies.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de RAFA?
RAFA actualmente puntúa 44/100 (Grado D) en el MoonshotScore, lo que sugiere calificación baja. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de RAFA?
Los precios de RAFA se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre RAFA?
La cobertura de analistas para RAFA incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en RAFA?
Las categorías de riesgo para RAFA incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Ongoing: Intense competition from domestic and international pharmaceutical companies.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de RAFA?
La relación P/E para RAFA compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está RAFA sobrevalorada o infravalorada?
Determinar si Rafarma Pharmaceuticals, Inc. (RAFA) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de RAFA?
Rafarma Pharmaceuticals, Inc. (RAFA) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Information is based on available data and may be limited due to the company's OTC listing and limited public disclosures.
- AI analysis pending for RAFA.